Systemic fluoroquinolones remain commonly prescribed broad-spectrum antibiotics, both in hospital and outpatient settings, despite rising resistance rates [1–7]. Since their approval, fluoroquinolones were associated with serious adverse events (AEs), such as Clostridium difficile infection, fatal arrhythmia due to QT prolongation, hepatotoxicity, severe haemolytic-uremic syndrome and dysglycemia, leading to the market withdrawal of some compounds (temafloxacin, trovafloxacin, grepafloxacin and gatifloxacin) [8–13].
